Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01488526
Other study ID # IN-US 174-0174
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 1, 2012
Est. completion date June 28, 2018

Study information

Verified date December 2019
Source New Discovery LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Immunoprophylaxis failure of hepatitis B virus (HBV) leading to vertical transmission remains a concern and has been reported in approximately 8-15% of infants born to hepatitis B e antigen (HBeAg) positive mothers with high levels of HBV DNA. Maternal HBV DNA > 6log10 copies/mL (or >200,000 IU/mL) is the major risk for the mother-to-child transmission. Prior observational studies have shown that antiviral therapy including lamivudine or telbivudine use during late pregnancy can safely reduce the rate of vertical transmission in this special population compared to untreated patients.

Tenofovir Disoproxil (TDF), a pregnancy category B medication, reduces HBV DNA and normalizes serum alanine aminotransferase (ALT) in chronic hepatitis B patients (CHB) with few adverse effects. Two aspects on tenofovir use in pregnancy will be evaluated prospectively in this study:

1. The data on its tolerability and safety in HBeAg+ pregnant women with HBV DNA > 6log10 copies/mL (or > 200,000 IU/mL) during late pregnancy and infants.

2. Its efficacy in the reduction of HBV vertical transmission rate.


Description:

Eligible mothers will be randomized (1:1) to either TDF-treated group or untreated group with about 100 subjects in each arm. The treatment group will receive TDF starting at week 30-32 of gestation until week 4 postpartum; follow up will continue until post-partum week 28 and infants age of 28 weeks. Untreated group will receive the standard of care with similar follow-up schedule as the treatment group.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 28, 2018
Est. primary completion date April 28, 2014
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- documented CHB infection with HBsAg positive > 6 months

- HBeAg+ CHB pregnant women

- gestational age between 30-32 weeks

- HBV DNA > 6 log10 copies/mL (or >200,000 IU/mL)

- both mother and father of the child are willing to consent for the study

Major Exclusion Criteria:

- co-infection with hepatitis A, C, D, E, HIV-1 or sexually transmitted disease (STD)

- decompensated liver disease or significant co-morbidity

- history of abortion, or diagnosis of fetal defect, or congenital malformation in prior pregnancy

- antiviral used within six months prior to this pregnancy, or history of renal or tubular function impairment due to adefovir.

- requirement for other medication during pregnancy to manage other chronic disease(s) or concurrent treatment with immune-modulators, cytotoxic drugs, or steroids

- the biological father of the child had CHB

- clinical signs of threatened miscarriage in early pregnancy

- evidence of hepatocellular carcinoma

- maternal alanine aminotransferase (ALT) > or = 5 x upper limit of normal (U/mL), or Total Bilirubin > or = 2, or glomerular filtration rate (GFR) < 100, or Albumin < 25 g/L

- evidence of fetal deformity by ultrasound examination

- patient is participating other clinical study

Study Design


Intervention

Drug:
TDF treatment
About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.

Locations

Country Name City State
China Hepatobiliary Disease Hospital of Jilin Province Chang Chun Jilin
China Southwest Hospital Chongqing Chongqing
China The Second Affiliated Hospital of the Southeast University Nanjing Jiangsu
China Nanyang Central Hospital Nanyang Henan
China The Fifth Hospital of Shijiazhuang Shijiazhuang Hebei

Sponsors (2)

Lead Sponsor Collaborator
New Discovery LLC Gilead Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure the number of infants who have HBV infection at the age of 28 weeks From the date of birth to age of 28 weeks
Primary Assessment of the safety and tolerability of TDF, measure the number of participants and paired infants with adverse events From the date of randomization until 28 weeks of postpartum.
Secondary Measure maternal HBV DNA reduction during the study period when compared to the baseline From the date of radomization to the time of delivery (upto 12 weeks from the radomization)
Secondary Measure maternal HBV DNA reduction during the study period when compared to the baseline From the date of radomization to the time of delivery (about 8 - 10 weeks from the radomization)
Secondary percentage of mothers with sero-negativity or sero-conversion of HBsAg and/or HBeAg in each group for comparison From the date of randomization until 28 weeks of postpartum.
See also
  Status Clinical Trial Phase
Recruiting NCT04704024 - Reducing Vertical Transmission of Hepatitis B in Africa Phase 3
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00371150 - Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Phase 4
Active, not recruiting NCT03519113 - HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 Phase 2/Phase 3
Completed NCT01788371 - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Recruiting NCT06368479 - Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings N/A
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
Completed NCT00489099 - A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) Phase 3
Recruiting NCT03476083 - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission Phase 4
Recruiting NCT03865966 - Hepatitis B Virus Infection After Liver Transplantation in Children
Completed NCT03627507 - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Phase 2/Phase 3
Completed NCT02443233 - Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong N/A
Completed NCT00841477 - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users Phase 3
Terminated NCT03887702 - Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Phase 3
Completed NCT02304315 - A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients Phase 2
Active, not recruiting NCT05117541 - Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
Not yet recruiting NCT06368466 - A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites N/A